A changing healthcare landscape is placing new demands on the life sciences industry. Pipelines are evolving, focusing on highly targeted indications—and driving greater demand for deep scientific information across the healthcare community. Increasingly, pharma is contending with these shifts by growing medical affairs teams.
The first in our series on the evolution of medical affairs dives into the changing role of the medical affairs organization. Join Robert Groebel, vice president of global medical strategy, to learn how medical teams can make a strategic impact.